Prediction of response to neoadjuvant hormonal therapy (NAHT) using upfront oncotype Dx recurrence score (RS): Results from the SAFIA phase III trial.

Khalid Alsaleh,A. Bounedjar,M. Oukkal,Hasen Mahfouf,K. Bouzid,Assia Bensalem,Taha Fillali,Blaha Larbaoui,Alaa Kandil,Meteb Owaish Al-Foheidi,Hassan Errihani,Marwan Ghosn,Nashwa A Abdulaziz,Farida Dabouz,M.R.K. Bahadoor,Heba Mohamed El Zawahry,Sherif A Kullab,Jean-Marc Nabholtz

Prediction of response to neoadjuvant hormonal therapy (NAHT) using upfront oncotype Dx recurrence score (RS): Results from the SAFIA phase III trial.

2020

Khalid Alsaleh
A. Bounedjar
M. Oukkal
Hasen Mahfouf
K. Bouzid
Assia Bensalem
Taha Fillali
Blaha Larbaoui
Alaa Kandil
Meteb Owaish Al-Foheidi
Hassan Errihani
Marwan Ghosn
Nashwa A Abdulaziz
Farida Dabouz
M.R.K. Bahadoor
Heba Mohamed El Zawahry
Sherif A Kullab
Jean-Marc Nabholtz

594Background: While hormonal therapy (HT) is a fundamental treatment in breast cancer therapy, neoadjuvant NAHT is not considered standard. The SAFIA trial is a prospective international neoadjuva...

Keywords:

Physical therapy
Oncology
Hormonal therapy
recurrence score
Internal medicine
Oncotype DX
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations